Cargando…

Novel Monitoring and Dose Adjustment of Argatroban, a Direct Thrombin Inhibitor, to Maintain Therapeutic Anticoagulation in a Patient With Antiphospholipid Antibody Syndrome, Heparin-Induced Thrombocytopenia, and COVID-19 Pneumonia

In patients who require systemic anticoagulation, a reliable monitoring method is required to ensure anticoagulation is maintained within the correct therapeutic window and patients are treated appropriately. When titrating direct thrombin inhibitors (DTIs), dilute thrombin time (dTT) measurements h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryan, Christine E., Newman, Kelly A., Roberts, Russel J., Frydman, Galit H., Rosovsky, Rachel P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129108/ https://www.ncbi.nlm.nih.gov/pubmed/37114202 http://dx.doi.org/10.1097/CCE.0000000000000903

Ejemplares similares

Argatroban in the management of heparin-induced thrombocytopenia
por: Babuin, Luciano, et al.
Publicado: (2010)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Argatroban/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2021)

Anticoagulation with Argatroban in a Patient with Heparin-Induced Thrombocytopenia and Renal Insufficiency Undergoing Orthotopic Heart Transplantation
por: Green, Michael Stuart, et al.
Publicado: (2021)

Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
por: Grouzi, Elisavet
Publicado: (2014)

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
por: Tardy-Poncet, Brigitte, et al.
Publicado: (2015)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
por: Ogawa, Yoshihiko, et al.
Publicado: (2020)

A Case Report and Literature Review on Argatroban Refractory Heparin-Induced Thrombocytopenia
por: Deen, Imad U., et al.
Publicado: (2022)

Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia
por: Hasan, Haytham, et al.
Publicado: (2023)

Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
por: Colarossi, Giorgia, et al.
Publicado: (2021)

Managing argatroban in heparin‐induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin‐induced thrombocytopenia
por: Marchetti, Matteo, et al.
Publicado: (2022)

Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
por: Bredthauer, Andre, et al.
Publicado: (2020)

Argatroban for heparin-induced thrombocytopenia therapy in ICU patients with sepsis or multiple organ dysfunction syndrome
por: Saugel, B, et al.
Publicado: (2009)

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function
por: Yeh, Calvin H., et al.
Publicado: (2016)

Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19
por: Aliter, Kholoud F., et al.
Publicado: (2020)

Bleeding complications after cardiac surgery, before anticoagulation start and then with argatroban or heparin in the early postoperative setting
por: Klingele, Matthias, et al.
Publicado: (2020)

Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2010)

Successful Management of Heparin-Induced Thrombocytopenia Using Argatroban in a Very Old Woman: A Case Report
por: Putot, A., et al.
Publicado: (2013)

Argatroban caused severe hypercholesterolaemia in a chronic haemodialysis patient with heparin-induced thrombocytopenia: an unreported adverse effect?
por: Nakagawa, Tetsuya
Publicado: (2008)

Argatroban for an alternative anticoagulant in HIT during ECMO
por: Rougé, Alain, et al.
Publicado: (2017)

Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study
por: Fisser, Christoph, et al.
Publicado: (2021)

Correction: Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study
por: Saugel, Bernd, et al.
Publicado: (2012)

Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS
por: Brückner, Lea, et al.
Publicado: (2021)

Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass
por: Agarwal, Shvetank, et al.
Publicado: (2012)

The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT
por: Koster, Andreas, et al.
Publicado: (2007)

Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Argatroban for anticoagulation of a blood salvage system - an ex-vivo study
por: Beiderlinden, Martin, et al.
Publicado: (2016)

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism
por: Adediran, Samuel, et al.
Publicado: (2017)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia
por: Nilius, Henning, et al.
Publicado: (2021)

Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study
por: Billoir, Paul, et al.
Publicado: (2021)

Argatroban/azd-1222/dexamethasone: Thrombotic thrombocytopenia and lack of efficacy: 3 case reports
Publicado: (2021)

Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
por: Yokota, Yuya, et al.
Publicado: (2019)

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia
por: Mirdamadi, Ahmad
Publicado: (2013)

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban
por: Guetl, Katharina, et al.
Publicado: (2021)

In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia
por: Nygaard, Søren, et al.
Publicado: (2023)

A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra(®)) in Critically Ill Patients with Heparin Resistance †
por: Bachler, Mirjam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_198e62c9jujnu80phjarhmsad7